Combination of Two FDA Approved Drugs Shows Promise in BRAF V600E‒Mutated Glioma
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th meeting of the Society for…
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th meeting of the Society for…